Workflow
Lilly(LLY)
icon
Search documents
FDA approves updated label for Lilly's Kisunla (donanemab-azbt) with new dosing in early symptomatic Alzheimer's disease
Prnewswire· 2025-07-09 10:45
The newly recommended dosing schedule significantly lowered ARIA-E rates compared to the original dosing schedule, adding to the established safety profile of the treatmentINDIANAPOLIS, July 9, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved a label update with a new recommended titration dosing schedule for Kisunla (donanemab-azbt), Lilly's once-monthly amyloid-targeting therapy for adults with early symptomatic Alzheimer' ...
Don't Miss Out: 3 Blue-Chips Set to Pop This Earnings Season
MarketBeat· 2025-07-08 20:46
Economic Outlook - Analysts forecast an average of 5% year-over-year (YOY) earnings growth for S&P 500 companies, indicating a mix of optimism and caution among investors [1][2] - Growth expectations have recently increased, especially for tech stocks, although the growth rate is expected to be slower than the previous year [2] Investment Strategies - Companies are awaiting clarity on tariffs, which complicates accurate forecasting for analysts and investors [3] - Large-cap, blue-chip companies are recommended as a strategy to navigate uncertainty due to their strong balance sheets, cash flow, and pricing power [3] Company-Specific Insights Alphabet Inc. (GOOGL) - Current stock price is $174.12 with a 12-month price forecast of $200.00, representing a 14.86% upside [5] - In Q1, revenue increased by 12% YOY and earnings per share (EPS) rose by 49% YOY, with significant growth in Google Cloud [6] - The company is investing in future growth areas such as autonomous driving, AI chip development, and quantum computing, alongside a $70 billion share buyback [7] Eli Lilly and Company (LLY) - Current stock price is $781.06 with a 12-month price forecast of $1,011.61, indicating a 29.52% upside [9] - The company has a strong position in the GLP-1 drug category and is developing an oral version of its treatment [10] - LLY stock is projected to see earnings growth of over 34% in the next year, with a consensus price target of $1,012 [11] JPMorgan Chase & Co. (JPM) - Current stock price is $282.81 with a 12-month price forecast of $276.80, suggesting a slight downside of 2.13% [13] - The bank has achieved a total return of over 256% in the last five years, benefiting from higher interest rates [14] - Expected earnings growth for JPM is 7.2%, which is above the S&P average, and the company offers a dividend yield of 1.92% [15]
替尔泊肽、司美格鲁肽,减肥、护心最佳选择!
GLP1减重宝典· 2025-07-07 07:35
整理 | GLP1减重宝典内容团队 近日,湘雅二医院研究人员发表在柳叶刀子刊eClinicalMedicine上的一项系统综述和Meta分析,研究了在FDA和欧洲药监局批准上市的减肥 药。 结果表明, 对于减肥,替尔泊肽是首选,其次是司美格鲁肽 。考虑到心脏代谢风险因素, 替尔泊肽显示出最佳的降血压和降血糖效果,而司 美格鲁肽和利拉鲁肽可降低 MACE 风险 。纳曲酮/安非他酮有升高血压的风险。芬特明/托吡酯有较高的心理副作用风险,应谨慎使用。尽管 存在与研究异质性相关的局限性,但这些发现为不同个体的体重管理策略提供了宝贵的见解。 ▍研究背景 超重和肥胖对个人和社会构成了严重的健康挑战。本研究旨在通过总结最近关于减肥药物疗法的研究来促进肥胖的个性化治疗,重点关注其对 减肥、心脏代谢健康、心理结果和不良事件的影响。 ▍ 研究 方法 本系统评价和荟萃分析包括从开始到 2024 年 6 月 8 日对 Web of Science、PubMed 和 Cochrane 对照试验中心注册库的搜索。纳入了评估美国 食品药品监督管理局 (FDA) 或欧洲药品管理局 (EMA) 批准用于治疗超重或肥胖的减肥药物疗法的随机对照试 ...
国产减重药“上市潮”闸门打开,跨国巨头如何应对
第一财经· 2025-07-06 11:38
2025.07. 06 本文字数:5463,阅读时长大约9分钟 作者 | 第一财经 钱童心 伴随着国产GLP-1减重药玛仕度肽(商品名:信尔美)的商业化落地,国内减重药市场格局迎来了 新的变化。全球两大减重药巨头诺和诺德与礼来在中国市场将面临更激烈的竞争环境,减重药未来价 格是否会出现松动也引发关注。 减重药市场迎来"新玩家" 7月3日,信达生物的GLP-1减重创新药玛仕度肽"首方"落地。北京大学人民医院分泌科主任医师纪 立农教授为一名超重合并脂肪肝的患者开出全国首张处方,标志着玛仕度肽正式进入国内公立医院。 这距离该药物获批仅一周之隔。下周起,该药物将陆续进入全国各大公立医院。 相比之下,诺和诺德的司美格鲁肽减重适应症(商品名:诺和盈)从获批到正式商业化开出公立医 院"首方"历时近5个月;礼来的替尔泊肽减重适应症从获批到上市也经历了近半年时间。 "国内厂商没有产能供应限制的问题。"一位业内人士对第一财经记者。另据记者了解,直到目前为 止,司美格鲁肽与替尔泊肽均尚未在国内实现本土化生产。 在信达生物此前召开的产品上市发布会上,信达生物首席财务官由飞表示,对于玛仕度肽的市场潜 力,公司非常有信心。在渠道拓展方面 ...
2 Dividend Growth Stocks to Buy and Hold Forever
The Motley Fool· 2025-07-06 11:05
Group 1: Zoetis - Zoetis is a leading animal health company with a diverse portfolio, including 15 products generating over $100 million in annual sales, and has achieved a compound annual growth rate of 8% from 2014 to 2023, outperforming the industry average of 5% [4] - Despite facing competition, particularly with recent drug approvals challenging its growth driver Apoquel, Zoetis has a strong track record of innovation and continues to launch new products like Solensia and Librela, which treat osteoarthritis pain in pets [5][6] - The company benefits from long-term trends such as the growing pet population and increased demand for protein sources due to human population growth, positioning it well for future growth [7][8] - Zoetis has a solid dividend program with a forward yield of 1.3% and has increased its payouts by 502% over the past decade, maintaining a conservative payout ratio of 31.6%, allowing for potential future increases [9] Group 2: Eli Lilly - Eli Lilly has seen significant growth in revenue and earnings, with a 45% year-over-year increase in the first quarter, reaching $12.7 billion, and has doubled its dividends over the past five years [10] - The company has a diversified portfolio with blockbuster medicines in various therapeutic areas, including immunology and oncology, and a promising pipeline with products like Kisunla for Alzheimer's disease, which could generate over $1 billion in annual sales [11][12] - Despite a low forward yield of 0.8%, Eli Lilly's solid track record and a modest cash payout ratio of 44% indicate its attractiveness as a buy-and-hold option for dividend investors [13]
世界卫生组织:司美格鲁肽等GLP-1具有“变革性”潜力
GLP1减重宝典· 2025-07-06 07:11
整理 | GLP1减重宝典内容团队 这些言论是周三在JAMA的一篇评论文章中发表的,由世卫组织官员Jeremy Farrar、Francesco Branca和Francesca Celletti撰写。 在文章中,专家们称肥胖是一个"大流行"的公共卫生问题, 影响全球10多亿人,几乎每个国家的病例都在增加。2019年,肥胖相关的非传染性 疾病夺走了500万人的生命。到 2030 年,全球肥胖相关成本可能达到 3 万亿美元 。 据世界卫生组织称,GLP-1受体激动剂目前正以高度医疗化的方式使用。 医疗保健系统需要制定更全面的解决方案,重点关注健康促进、疾病 预防和政策干预。 世界卫生组织官员认为, GLP-1 肥胖疗法的迅速崛起为该行业和医疗保健系统提供了对抗肥胖大流行的有力武器,但目前 的部署方式有可能无法实现这一目标。 在此背景下,GLP-1 受体激动剂的兴起和日益普及可能会对肥胖护理产生"变革性"影响,为各国卫生系统提供有效的药物治疗选择。 "然而,单独的药物治疗不足以解决肥胖危机,"世卫组织官员写道,并补充说,医疗保健系统必须采取整体应对措施,"确保普遍提供预防、治 疗和管理疾病的服务,使之易于获得、负 ...
礼来+诺和双重减肥药=超级王炸!72周减重22.1%,92.9%自于脂肪!
GLP1减重宝典· 2025-07-05 09:51
Core Viewpoint - The combination of Bimagrumab and Semaglutide shows significant efficacy in weight management, with an average weight loss of 22.1% over 48 weeks, primarily from fat reduction, indicating a comprehensive strategy for obesity treatment [2][4]. Group 1: Clinical Trial Results - In a 48-week trial, participants receiving the combination treatment lost an average of 22.1% of their body weight, with 92.8% of this loss attributed to fat reduction, compared to a 15.7% weight loss with Semaglutide alone, where 71.8% was fat loss [2]. - The combination therapy not only resulted in greater weight loss but also preserved more lean body mass, which is particularly important for populations at risk of sarcopenia [4]. Group 2: Significance of the Research - The study addresses a major public health issue, as obesity is linked to various complications such as diabetes, heart disease, and certain cancers, and the combination therapy may improve the quality of life for many patients [4]. - Bimagrumab's development is part of Eli Lilly's ongoing innovation strategy in obesity treatment, focusing on the often-overlooked issue of muscle preservation during weight loss [4]. Group 3: Future Directions - Eli Lilly is also advancing clinical trials for Bimagrumab in combination with Zepbound, a dual-target GLP-1/GIP agonist, expanding treatment options for patients and healthcare providers [5]. - The acquisition of Versanis Bio for approximately $2 billion highlights the company's commitment to exploring new avenues in weight management, particularly targeting ActRII [6]. Group 4: Mechanism of Action - Bimagrumab targets the activin receptor type II (ActRII), which plays a crucial role in muscle growth regulation, and its inhibition may provide a more effective approach to preserving muscle mass during weight loss [12][13]. - The signaling pathway involving ActRII has implications for muscle diseases, and targeting this receptor could lead to advancements in treating conditions like sarcopenia and cachexia [9][13].
【掘金行业龙头】阿尔茨海默+减肥药,阿尔茨海默领域服务欧美药企,为小分子减肥药提供中间体,这家公司客户包括礼来、辉瑞等巨头
财联社· 2025-07-04 03:50
阿尔茨海默+减肥药,阿尔茨海默领域服务欧美药企,为小分子减肥药提供中间体,客户包括礼来、辉瑞 等巨头,在中美均设有研发生产中心,这家公司可为客户提供含氟药物中间体或原料药的定制服务。 前言 《电报解读》是一款主打时效性和专业性的即时资讯解读产品。侧重于挖掘重要事件的投资价值、分析 产业链公司以及解读重磅政策的要点。即时为用户提供快讯信息对市场影响的投资参考,将信息的价值 用专业的视角、朴素的语言、图文并茂的方式呈现给用户。 ...
礼来替尔泊肽获批睡眠呼吸暂停适应证;诺泰生物预计半年度净利润最高增长45%丨医药早参
Mei Ri Jing Ji Xin Wen· 2025-07-03 23:52
7月3日,迪哲医药公告称,舒沃哲(通用名:舒沃替尼片)的新药上市申请,正式获得美国食品药品监 督管理局(FDA)批准,用于既往经含铂化疗治疗时或治疗后出现疾病进展,并且经FDA批准的试剂盒 检测确认,存在表皮生长因子受体(EGFR)20号外显子插入突变(exon20ins)的局部晚期或转移性非 小细胞肺癌(NSCLC)的成人患者。 点评:舒沃哲是中国首个独立研发、在美获批的全球首创新药,此次获批有望提升迪哲医药在国际市场 的声誉,也为国产创新药出海提供了新的示范案例。 NO.3 先声药业恩泽舒获批上市,为中国首个铂耐药卵巢癌全人群适用靶向药 7月3日,先声药业旗下创新药子公司先声再明宣布,其在中国开发的新一代抗肿瘤血管生成(抗VEGF 抗体)一类生物新药恩泽舒(通用名:注射用苏维西塔单抗)已正式获中国国家药品监督管理局批准上 市。恩泽舒获批适应证为联合紫杉醇、多柔比星脂质体或拓扑替康用于铂耐药后接受过不超过1种系统 治疗的成人复发性卵巢癌、输卵管癌或原发性腹膜癌的治疗。 每经记者|许立波 每经编辑|张益铭 丨2025年7月4日 星期五丨 NO.1 礼来替尔泊肽获批第三项适应证 7月3日,礼来宣布,其GIP/G ...
X @Ansem
Ansem 🧸💸· 2025-07-03 14:26
AI & Technology - Google: Gemini is favored to win in AI, benefiting YouTube and Google Cloud; Waymo's automation potential is not fully valued; Sergey Brin's return is noted [1] - Alibaba: Impressed with their AI (Qwen), considered a top 3 AI lab in China [2] - Tencent: Owns the largest social network in China, a great business with founder-led management, also considered a top 3 AI lab in China [2] - Xiaomi: A pure play on EVs, especially with Elon Musk's focus shift; offers great inexpensive cars; behind on FSD but expected to catch up in a couple of years; founder-led [2] Healthcare & Pharmaceuticals - Eli Lilly: GLP-1 drugs may cure chronic diseases beyond fat loss; the market is too big to ignore; based in the US, which has a large chronically unhealthy population; has been consolidating for a year [2] Investment Strategy - Avoiding US tech stocks generally due to valuation, but Google is reasonably priced [1] - Investments in stocks are to force attention to interesting things [2]